ScinoPharm Taiwan Ltd. engages in the research, development, manufacturing, and sales of active pharmaceutical ingredients and injections. It also provides consulting and biotechnology services.It operates through the following segments: ScinoPharm Taiwan, Ltd., SciAnda (Changshu) Pharmaceuticals Ltd., and Others. The company's products include abiraterone acetate, anastrozole, apixaban, apremilast, atazanavir sulfate, azacitidine, benazepril hydrochloride, bortezomib, capecitabine, celecoxib, cladribine, dantrolene sodium, decitabine, desmopressin acetate, docetaxel anhydrous, docetaxel trihydrate, entecavir, enzalutamide, exemestane, flumazenil, fulvestrant, galantamine, gefitinib, gemcitabine hydrochloride, ondansetron hydrochloride, and paclitaxel. The company was founded on November 11, 1997 and is headquartered in Tainan, Taiwan.
Fundamental metrics to determine fair value of the stock
Company’s recent performance and margins
Dividend yield, history and sustainability
Financial position and solvency of the company